{"id":3009,"date":"2016-07-29T21:46:03","date_gmt":"2016-07-29T21:46:03","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=16768"},"modified":"2016-07-29T21:46:03","modified_gmt":"2016-07-29T21:46:03","slug":"dr-titus-insights-follow-nfl-cte-news","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/07\/29\/dr-titus-insights-follow-nfl-cte-news\/","title":{"rendered":"Dr. Titus’ Insights: Follow Up on NFL & CTE News"},"content":{"rendered":"
This week, our CEO Dr. Stuart Titus brings perspective to the recent media coverage of cannabis’ potential as a treatment for Chronic Traumatic Encephalopathy, the brain disorder caused by repeated head trauma that has afflicted many football players.<\/p>\n
—<\/p>\n
A\u00a0killer article entitled appeared in Forbes this week, by journalist Deborah Borchardt. \u00a0A link to the article is here<\/a> and is required reading for anyone wanting more knowledge on potential treatments\u00a0for CTE.\u00a0<\/span><\/p>\n Deborah Borchardt really knocked it out of the ballpark with her tremendous coverage of the relevant issues affecting the NFL in regards to CTE. \u00a0I thought my readers may enjoy some further research which may have relevance to the treatment of\u00a0CTE issue. \u00a0This treatment may well have implications for Alzheimer’s Disease<\/a> as well as Traumatic Brain Injury (TBI)<\/a> patients.<\/span><\/p>\n NFL Seeks New Medical Director<\/b><\/p>\n We did see this week a potential change in NFL CTE policy as the NFL and Commissioner Roger Goodall announced the \u201cearly retirement\u201d of the NFL\u2019s Chief Medical officer, Dr. Elliott Pellman. \u00a0Basically many players (and presumably many NFL Owners, NFL Management) criticized Dr. Pellman for his lack of knowledge and grasp of the CTE situation. \u00a0Dr. Pellman once, famously, downplayed the risks of head injury and football. \u00a0A search is now on for a new, presumably more CTE progressive Medical Director. \u00a0Story: <\/span>http:\/\/www.foxsports.com\/nfl\/story\/roger-goodell-hire-new-chief-medical-officer-eliot-pellman-retire-concussions-brain-trauma-cte-072016<\/span><\/a><\/p>\n Alzheimer\u2019s Research and Possible CTE Implications<\/b><\/p>\n Going into the science just a bit further, I have noted a recent early stage clinical study performed locally here in San Diego by the Salk Institute and Dr. David Schubert. \u00a0The research study, published in late June 2016 titled: <\/span>Cannabinoids Remove Plaque Forming Alzheimer’s Proteins From Brain Cells<\/span><\/i> and subtitled: Preliminary Lab Studies at The Salk Institute Find THC Reduces Beta Amyloid Proteins in Human Neurons.\u00a0<\/span><\/p>\n Link:\u00a0<\/span>https:\/\/www.salk.edu\/news-release\/cannabinoids-remove-plaque-forming-alzheimers-proteins-from-brain-cells\/<\/span><\/a> \u00a0<\/span><\/p>\n Beta amyloid is a toxic protein accumulation that occurs in brain cells and similar to a roadblock on a main interstate highway – these accumulations, over time interfere with and potentially destroy nerve communication cells and cell lines of communication. \u00a0Beta amyloid is a characteristic of Alzheimer’s patients. \u00a0Dr. Schubert’s study was on human brain cells, but performed in petri dish models and not full human subjects. \u00a0Nonetheless this opens the door to future human research.<\/span><\/p>\n Note that pharmaceutical development is 0 for 190 tries to find an answer that will as little as halt the downward progression of Alzheimer’s disease. \u00a0<\/span><\/p>\n Link:\u00a0<\/span>http:\/\/www.bloomberg.com\/news\/articles\/2016-06-27\/after-190-tries-are-we-any-closer-to-a-cure-for-alzheimer-s<\/span><\/a> \u00a0<\/span><\/p>\n Cannabinoids may provide an answer…<\/span><\/p>\n Tau Protein<\/b><\/p>\n A similar-to-beta-amyloid protein accumulation is Tau protein accumulation. \u00a0Tau protein deposits are characteristic of CTE – and only able to be diagnosed in post-mortem autopsies. \u00a0Of 91 ex-NFL player\u2019s brains donated to VA Boston Healthcare System \/ Boston University\u2019s Brain Research Center and Dr. Ann McKee, 87 have tested positive for CTE.<\/span><\/p>\n Link: <\/span>http:\/\/www.pbs.org\/wgbh\/frontline\/article\/new-87-deceased-nfl-players-test-positive-for-brain-disease\/<\/span><\/a><\/p>\n If cannabinoids can be shown to similarly reduce tau protein accumulations – then we may have answers for both Alzheimer’s as well as CTE. \u00a0Like beta amyloid, the Tau protein deposits act as roadblocks on interstate highways – interfering with nerve signals and transmission of vital brain communication networks. \u00a0As these toxic brain protein accumulations build up over time, increasing numbers of brain cells die off, exacerbating the communication problem.<\/span><\/p>\n Synaptic Density<\/b><\/p>\n The loss of neuronal cells and the loss of synaptic density in particular, is a biomarker for Alzheimer\u2019s. \u00a0As the synapse is the area of the neuronal network where the signal \u201cjumps the gap\u201d between neurons, this is a major target for pharmaceutical intervention. \u00a0In reality, 100% of pharmaceutical intervention for neurological conditions targets the synapse \u2013 BUT only 2% of ALL neuronal communication occurs here (Source: Electro-Medical Products International, EMPI). \u00a0Thus the failure of traditional medicine to effectively treat any neurological disorder including:<\/span><\/p>\n It seems as though Cannabinoids can access the full spectrum of neurological communication \u2013 going well beyond the synapse. \u00a0A Dr. Marie Walbridge hosts an excellent 5 minute YouTube video entitled Dancing Neurons<\/em> here<\/a>.<\/span><\/p>\n Cannabinoids May Offer Hope<\/b><\/p>\n Thus the promise of cannabinoids and cannabinoid medications to potentially:\u00a0<\/span><\/p>\n (a) in natural botanical form, be used as a preventative with all high school, college and even pro football players on a hemp-based CBD regimen<\/span><\/p>\n (b) in pharmaceutical form, for those who have suffered traumatic brain injury (TBI) or full concussion event.<\/span><\/p>\n To this pharmaceutical approach, our team at Kannalife Sciences Inc. is hard at work and have developed a lead molecule, KLS-13019. \u00a0This molecule, a cannabinoid-like neuroprotectant, has demonstrated in pre-clinical efforts, significant neuroprotective capabilities. \u00a0Congratulations to Kannalife CEO, Dean Petkanas; Kannalife co-Founder Thoma Kikis; Chief Scientific Officer, Dr. William Kinney and Dr. Doug Brenneman, Chief Medical Officer. \u00a0Dr. Brenneman believes he may be close to describing an actual \u201cmechanism of action\u201d regarding the neuroprotective properties of KLS-13019, which would mark another milestone achievement for the Kannalife team. <\/span><\/p>\n Multi-Channel Approach<\/b><\/p>\n For the Alzheimer\u2019s population, if this research holds true \u2013 again we would offer a two-pronged approach. First for those potentially at-risk, we would have them on the CBD natural botanical hemp-based product as an early preventative. \u00a0Then for the later stage, advanced Alzheimer\u2019s patient \u2013 we would offer a pharmaceutical developed product \u2013 possibly this KLS-13019 or a similarly developed product by the Kannalife team.<\/span><\/p>\n Again \u2013 this is all speculative, as many compounds hold excellent promise in pre-clinical work \u2013 only to disappoint in later stage human trials. \u00a0But with no\u00a0available pharmaceutical treatments for TBI \/ CTE and with few viable pharmaceutical options for Alzheimer\u2019s \u2013 we remain optimistic that these challenges can be overcome by cannabinoid-based therapeutics.<\/span><\/p>\n Certainly when one starts to supplement the largest self-regulatory system within the human body, the endogenous cannabinoid system, good things seem to happen regarding people\u2019s health and wellness.<\/span><\/p>\n Long term we feel that the hemp-based CBD, with hemp and the essential fatty acids serving as “brain food” combined with the US Government researched neuroprotective effects of CBD – provides a wonderful long term solution to many problems faced by at-risk-for-concussion sport athletes. \u00a0US Government Patent titled: <\/span>Cannabinoids as Antioxidants and Neuroprotectants<\/a>.<\/span><\/i><\/p>\n Further, that success here, may lead us to similar success with the challenge of Alzheimer\u2019s and related dementia patients.<\/span><\/p>\n We look forward to providing further updates as our clinical efforts continue.<\/span><\/p>\n To Good Health \u2013<\/span><\/p>\n Stu<\/span><\/p>\n Stuart W Titus, PhD This week, our CEO Dr. Stuart Titus brings perspective to the recent media coverage of cannabis’ potential as a treatment for Chronic Traumatic Encephalopathy, the brain disorder caused by repeated head trauma that has afflicted many football players. — A\u00a0killer article entitled appeared in Forbes this week, by journalist Deborah Borchardt. \u00a0A link to the […]<\/p>\n","protected":false},"author":1,"featured_media":2104,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[3,195,163,9],"tags":[],"class_list":["post-3009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","category-dr-titus-insights","category-kannalife-sciences","category-scientific-research"],"yoast_head":"\n\n
\n<\/span>President & CEO
\n<\/span>Medical Marijuana Inc. (OTC: MJNA)<\/span> \t<\/p>\n","protected":false},"excerpt":{"rendered":"